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Abstract
Background: Congenital hypogonadotrophic hypogonadism (CHH) and Kallmann syndrome (KS) are caused by
disruption to the hypothalamic-pituitary-gonadal (H-P-G) axis. In particular, reduced production, secretion or action
of gonadotrophin-releasing hormone (GnRH) is often responsible. Various genes, many of which play a role in the
development and function of the GnRH neurons, have been implicated in these disorders. Clinically, CHH and KS
are heterogeneous; however, in 46,XY patients, they can be characterised by under-virilisation phenotypes such as
cryptorchidism and micropenis or delayed puberty. In rare cases, hypospadias may also be present.
Results: Here, we describe genetic mutational analysis of CHH genes in Indonesian 46,XY disorder of sex development
patients with under-virilisation. We present 11 male patients with varying degrees of under-virilisation who have rare
variants in known CHH genes. Interestingly, many of these patients had hypospadias.
Conclusions: We postulate that variants in CHH genes, in particular PROKR2, PROK2, WDR11 and FGFR1 with CHD7, may
contribute to under-virilisation phenotypes including hypospadias in Indonesia.
Keywords: Congenital hypogonadotrophic hypogonadism, Under-virilisation, Hypospadias, Targeted gene sequencing,
Disorder of sex development
Background
Proper function of the hypothalamic-pituitary-gonadal
(H-P-G) axis is essential for the development of the
reproductive system. Gonadotrophin-releasing hormone
(GnRH), secreted by the hypothalamus, stimulates the
biosynthesis and the release of gonadotrophins from the
anterior pituitary gland. These gonadotrophins (luteinis-
ing hormone (LH) and follicle-stimulating hormone
(FSH)) both play distinct roles in the gonads during
embryonic development. In males, FSH stimulates the
proliferation of immature Sertoli cells and spermatogonia
[1]. FSH also stimulates the secretion of inhibin, which
acts in a negative feedback loop directly to the anterior pi-
tuitary. LH stimulates the production and secretion of tes-
tosterone from the Leydig cells, which is thought to occur
through the LH receptor after 10 weeks post conception
[2]. Disruption to the H-P-G axis (through deficient
production, secretion or action of the gonadotrophins)
can result in hypogonadotrophic hypogonadism (HH).
While this can be associated with additional anomalies or
syndromes such as Dandy-Walker syndrome, Gorden
Holmes syndrome and CHARGE [3], when observed
alone, it is termed congenital or idiopathic HH (CHH)
(OMIM 146110). CHH can be coupled with a decreased
or absent sense of smell due to the abnormal migration of
the GnRH neurons [4, 5]. The co-occurrence of CHH with
anosmia is termed Kallmann syndrome (KS (OMIM
308700, 147950, 244200, 610628, 612370 and 612702)).
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Estimates of the prevalence of CHH range between 1
and 10 in 100,000 live births, with approximately two
thirds of cases arising from KS [6]. CHH in 46,XY males
can cause a reduced level of circulating androgens due
to hypogonadism. Isolated or apparently isolated CHH
(i.e. in a patient with KS who does not complain of an
absent or diminished sense of smell) is most commonly
diagnosed in teenagers or young men who present with
pubertal failure. During foetal development, testosterone
is responsible for virilisation of the reproductive tract
and dihydrotestosterone (DHT), a highly potent deriva-
tive of testosterone, drives differentiation of the external
genitalia. The appearance of clinical characteristics de-
pends on when HH begins. When GnRH deficiency occurs
in the late foetal or early neonatal periods, a significant de-
crease in androgens can lead to some CHH patients being
diagnosed postnatally with under-virilisation phenotypes
such as cryptorchidism, micropenis [7] and, in some rare
cases, hypospadias [8]. Patients also typically showed de-
layed or absent puberty including minimal virilisation, low
libido, lack of sexual function and a reduced or absent
growth spurt [3]. In addition to the physical anomalies,
physiological impairments have also been reported such as
low self-esteem, distorted body image and, in some cases,
problems in sexual identity [9, 10]. Finally, CHH may be
diagnosed following adolescence, later in life when infertil-
ity is a concern. Given these complex and significant phys-
ical and psychological implications, early diagnosis and
treatment of CHH is essential. Clinically, CHH can pheno-
copy partial androgen insensitivity syndrome (PAIS) or
other disorders of sex development (DSDs) in which a
reduction of testosterone during development can cause
reduced virilisation. If blood hormone testing is not rou-
tinely carried out, these patients may be misdiagnosed and
clinical management may differ.
Genetically, CHH is highly complex. More than 30
genes have been implicated in CHH and/or KS including
nine genes that cause an overlapping syndrome [3]. To
complicate matters, a large degree of variability in inherit-
ance, penetrance and expressivity is seen in CHH and an
increasing body of evidence suggests that this disorder can
be caused by variants in more than one gene (oligogeni-
city) [11, 12]. Variants in known CHH genes currently
account for only 50% of CHH cases [13] meaning that
more genes are yet to be found. Here, we present genetic
mutational analysis of CHH genes in Indonesian 46,XY
patients presenting with under-virilisation phenotypes.
Materials and methods
Clinical data
Patients with 46,XY DSD were referred to the Center for
Biomedical Research, Faculty of Medicine, Diponegoro
University (FMDU), Semarang, Indonesia. The medical
ethics committee of the Dr. Kariadi Hospital/FMDU
approved this study, and informed consent was obtained
from all participants, as well as their parents or guardians,
prior to their participation in this study. Following in-
formed consent, a detailed interview was performed at
recruitment and data concerning medical history, age of
initial presentation, sex of rearing, family history (relatives
with a genital disorder) and consanguinity were collected.
Patients were clinically evaluated by a trained andrologist;
a detailed description of the external genitalia was ob-
tained and, in many cases, images taken. A blood sample
was obtained for karyotyping, hormonal analysis and
DNA extraction. Referral and data collection took place
between 2004 and 2010. Eighty-eight of these patients
have been described previously [14]. A total of 47 males
with 46,XY under-virilisation phenotypes (including
uni- or bilateral cryptorchidism, hypospadias, bifid
scrotum, micropenis and, in some cases, severe hypo-
spadias) were included in this study. Hormone analysis
was carried out for some patients including base level
LH and FSH and testosterone (T). Reference levels for
FSH and LH are based on paediatric measurements de-
pending on age [15]. In some cases, T levels were also
measured following Leydig cell stimulation by human
chorionic gonadotrophin (hCG). For more details on
blood hormone analysis, see [14].
Gene panel sequencing
Genomic DNA was obtained from peripheral EDTA-
blood samples using the salting out method [16]. The
DNA underwent quality control at the Murdoch Childrens
Research Institute (MCRI), Melbourne, Australia. Total
genomic DNA was sequenced using a targeted panel
(Haloplex, Agilent) that covers 64 diagnostic DSD genes
[17]. This included 19 genes implicated in CHH (CHD7,
GNRH1, GNRHR, HESX1, LEP, PROKR2, PROP1, TAC3,
FGFR1, KAL1, LHX3, FGF8, PROK2, KISS1R, WDR11,
SPRY4, FSHB, CGA, SOX10). Library preparation and
sequencing were carried out as detailed in [17]. Raw data
was analysed using a modified pipeline created at
MCRI—C-pipe, which calls variants and provides data on
frequency and pathogenicity [18].
Following C-pipe analysis, variants were checked for
quality and depth and were filtered for those less than
1% minor allele frequency (MAF) in both the ESP6500
and 1000 genome project. As non-affected controls from
Indonesia were not included, variants that were found
very frequently in our screen (greater than 5% of total
samples run) were also discounted. We manually check
variant frequency in EVS and extracted ExAC data on
frequency in Asia (South Asia and East Asia). Variants
were checked for previous implication in human disease
via ClinVAR and HMGD. Predicted pathogenicity of
each variant was analysed using a range of up-to-date in
silico prediction tools (SIFT, PolyPhen-2, LRT and
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MutationTaster). Effects on protein structure and func-
tion were predicted using the HOPE tool [19].
Results
Patient cohort
All forty-seven 46,XY DSD patients from Indonesia were
first analysed for mutations in DSD genes that cause an-
drogen insensitivity or reduced testosterone production
(e.g. androgen receptor (AR), SRD5A2, HSD17B3). Rare
and damaging mutations in these genes were found in
19 patients [17] of the 47. The other 28 did not have a
causative variant identified. These patients ranged in age
from newborn to 14 years old, with a variety of 46,XY
DSD phenotypes including hypospadias, bifid scrotum,
cryptorchidism/undescended testis, microtestis and micro-
penis. All patients identify as male. Many have undergone
hypospadias repair. The phenotypes of the eleven patients
with a CHH variant are shown in Table 1, and representa-
tive images are shown in Fig. 1.
The hallmarks of CHH can include low levels of
testosterone (due to hypogonadism), which can often be
increased by hCG stimulation. Indeed, we found that all
of the patients tested showed moderate to high increases
in testosterone after hCG stimulation (Table 1). In
addition, low levels of LH and FSH are often indicative
of CHH; however, the natural levels of these hormones
are low during childhood. Indeed, most patients were
between mini-puberty and puberty when FSH/LH levels
are expected to be low (<0.1–4 IU/l for LH and <0.1–8 IU/
l for FSH). For all patients of this age, assayed LH and FSH
levels were within the normal range. Patient 169, who was
14 at the time, had an LH measurement of 2.7 IU/l, which
is within normal range, but an FSH of 9.24 IU/I, which is
considered slightly elevated. Patient 147 was within mini-
puberty at the time of measurement and subsequently had
an elevated LH level of 10.8 and FSH of 6.23. This may
suggest that secretion of these gonadotrophins is not inhib-
ited in this patient. Patient 143 did not have hormonal
analysis.
CHH genetic variants
The remaining 28 patients were then analysed for muta-
tions in the exonic regions of CHH genes as previously
detailed in [17]. Eleven patients had one or more rare
variants (<1% MAF in g1000 and ESP6500) in a CHH
gene (Table 2). In total, we found 14 variants in CHH
genes in these patients. The variants are described
below.
PROKR2
Four patients had variants in the PROKR2 gene. Two
patients (173 and 143) had the same variant—-
PROKR2:c.C563T:pS188L (Table 2). This variant has not
been found in our DSD panel previously (in over 300
DSD patients; see [17]) but has a total allele frequency
of 1.65e−05 in ExAC (although it has not been recorded
in SA or EA). This change has been recorded to be likely
pathogenic (ClinVar) [20, 21] (Table 2). Previous func-
tional analysis has shown this variant has a strong defect
in G-protein coupling [21]. The two patients with this
variant (patients 173, 143) had under-virilisation pheno-
types including micropenis, scrotal hypospadias and
cryptorchidism (Fig. 1, Table 1). Interestingly, one of
these patients also had additional anomalies. Patient 173
had spina bifida, incontinence and suspected intellectual
disability—suggesting additional genetic or environmen-
tal contributors (Table 1). Indeed, the mother of this
patient had a suspected folic acid deficiency during
pregnancy.
Two other patients had heterozygous missense vari-
ants in the PROKR2 gene (Table 2). c.G991A:p.V331M
was found in patient 159 who has perineal hypospadias
and unilateral cryptorchidism (Fig. 1, Table 1). This vari-
ant (rs117106081) has a total frequency in ExAC of
0.0065 (and was greater than 0.01 in both SA and EA).
It is not predicted to be damaging in any of the in silico
prediction tools and was not highly conserved. Never-
theless, this variant has been previously reported in
CHH/KS patients, and functional analysis in both publi-
cations suggested a reduction in function (in particular a
mild G-protein coupling defect) [21–23]. In contrast,
another variant c.T1054G:p.W352G was not found in
ExAC or EVS and was predicted to be damaging and
highly conserved among different species (Table 2 and
Fig. 2a). This was found in a patient 171, who has bilat-
eral cryptorchidism and scrotal hypospadias (Fig. 1 and
Table 1). In this case, the mutated residue is located on
the surface of a domain with unknown function (Fig. 2b).
The mutant residue (glycine) is smaller than the wild-type
residue and differs in hydrophobicity to the wild-type
residue (tryptophan). This may cause a loss of external in-
teractions in particular a loss of hydrophobic interactions
with other molecules on the surface of the protein.
From this, we hypothesise that PROKR2 variants, in
particular the variant p.S188L, represent a significant cause
of under-virilisation including cryptorchidism, micropenis
and, in some cases, hypospadias in Indonesian 46,XY DSD
patients.
PROK2
One patient (47) was found to harbour a variant in this
gene (PROK2:c.G68A:p.R23H). This missense heterozy-
gous variant was not found in any of the online data-
bases; however, it was not predicted to be pathogenic
(Table 2). This patient has a micropenis, scrotal hypo-
spadias and unilateral cryptorchidism (Table 1). The first
27 amino acids of PROK2 are a signal peptide, important
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for its secretion. The affected amino acid (arginine at
position 23) lies within this region.
WDR11
Three patients had heterozygous missense variants in
WDR11 (Table 2, patients 174, 164, 163). The first of
these was one of a pair of twins, who have concordant
phenotypes (patient 174, twin not analysed). This vari-
ant, WDR11:c.G2409T:p.W803C, was not found in
online databases and is predicted to be pathogenic with
strong conservation—even down to zebrafish (Table 2,
Fig. 2c). Patient 174 has a micropenis with penoscrotal
hypospadias and chordee (Fig. 1, Table 1). The second
variant found was WDR11:c.A1352G:p.H451R (Table 2).
This variant (rs199920020) has a total frequency of
0.0001 in ExAC but is rare in Asia and was found in a
patient with penoscrotal hypospadias and bifid scrotum
but no micropenis or cryptorchidism (patient 164,
Fig. 1, Table 1). Like the previous variant, this amino
acid is highly conserved (Fig. 2c). The third variant
(WDR11:c.T1279A:p.L427I) was not previously found
in any online databases and was predicted to be




















173 12 46,XY Male Bilaterally
non
palpable
Bifid Yes Scrotal Spina bifida Unknown Moderate




Bifid Yes Scrotal No Figure 1b
159 2 46,XY Male R, 1 ml,
scrotal
L, fetractile
Bifid No Perineal Unknown




Bifid Yes Scrotal No Yes Figure 1a








Bifid Yes Scrotal No Yes




Fused Yes Penoscrotal No Yes
164 3 46,XY Male Bilaterally
2 ml,
scrotal
Bifid No Penoscrotal No Yes
163 10 46,XY Male Bilaterally
3 ml,
scrotal
Bifid Yes Penile No Yes Figure 1c
147 1 m 46,XY Male R, inguinal
L, not
palpable
Bifid No Scrotal No Yes
101 3 46,XY Male Bilaterally
2 ml,
scrotal
Bifid Yes Scrotal Unknown Yes Figure 1d
169 14 46,XY Male R, 4 ml,
scrotal
Bifid no Penoscrotal No Yes
L, 6 ml,
scrotal
Patient identification number and age at first consultation are shown, as well as sex chromosome complement and gender. A description of anomalies is also
included. Response to hCG stimulation is shown. Testosterone reference levels were considered as 0.3–0.5 nmol/l except for patients 169, 163 and 8 (where
reference was considered 3–6.5 nmol/l)
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damaging and highly conserved (Fig. 2c). This was
found in patient 163, who has a micropenis and
penile hypospadias (Fig. 1, Table 1).
FGFR1
Three patients had the FGFR1 variant rs140382957
(FGFR1:c.C320T:p.S107L) (Table 2). This variant has a
MAF in EVS of 0.0077 and in ExAC of 0.0023 (and
while it is predicted to be pathogenic in two prediction
tools, one record in ClinVar has it logged as being
benign [24].)
CHD7
Curiously, two of the three patients who had a FGFR1
variant also had a variant in CHD7. One of these, CHD7:
c.G1565T:p.G522V has an ExAC MAF of 0.002318 and
was predicted damaging (Table 2); however, it has been
reported as benign for CHARGE on ClinVar. This was
found in patient 101. Another novel variant was rare
(ExAC MAF = 9.2e−05) (CHD7:c.C2347T:p.P783S). No
other CHD7 variants were found.
Discussion
In this study, we have investigated variants in CHH-
related genes in a cohort of Indonesian 46,XY DSD pa-
tients who had an under-virilisation phenotype. After
excluding patients with mutations in known DSD genes,
we found rare and damaging variants in CHH genes in
11 of the remaining 28 patients. CHH and KS can
present at birth with under-virilisation phenotypes in
males such as micropenis and cryptorchidism [25]. Our
study suggests that CHH may be a cause of under-
virilisation in Indonesia. While forty-seven 46,XY DSD
patients were initially recruited, 19 of these were found
to harbour mutation in a known DSD genes such as AR
(data not shown). Of the remaining 28, we found a likely
CHH variant(s) in 11 patients, making this a total of
25% of the total original cohort. In addition, while our
targeted DSD panel has a comprehensive list of diagnos-
tic DSD genes, it only covers 19 of approximately 24
genes that cause CHH/KS without an associated syn-
drome. Sequencing of the entire list of known CHH
genes, including those that cause CHH in association
with additional anomalies, may increase the diagnostic
yield of a genetic screen like this. This will be important
for future studies of this cohort.
Penile and urethral morphology is established before
14 weeks gestation meaning that the foetal pituitary-
hypothalamic axis is typically thought to be unnecessary
for normal penile development (instead relying on ma-
ternal hCG). However, after week 14, continued increase





Fig. 1 Under-virilisation in patients with CHH gene variants. a–d Representative images of external genitalia for four patients presenting with
46,XY DSD (see Table 1 for details)
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pituitary axis. Therefore, boys with hypogonadism will
often have micropenis but normal phallic morphology.
However, we found that many of individuals in our co-
hort had varying degrees of hypospadias. Given this, it is
interesting to note that while rare, hypospadias in pa-
tients with CHH or KS has been described. A large study
found two patients with CHH and hypospadias [26], and
several other studies have described patients with KS or
CHH and hypospadias of varying degrees [8, 27–29].
Nevertheless, hypospadias in CHH is a rare combination,
and it is interesting to speculate why our cohort has an
over-representation of variants in CHH genes in patients
with hypospadias. It is possible that in our cohort of
Indonesian patients, CHH and KS manifest in a
unique way, as we have not found this association in
patients with 46,XY DSD of other nationalities (data
not shown). Or, it may be that these variants simply
contribute to a phenotype in these patients that could
involve additional undetected variants in genes con-


















Fig. 2 Novel variants in CHH genes. Just one novel variant in PROKR2 was found (p.W352G). This change found in patient 171, c.T1054G:p.W352G,
is heterozygous and has good quality and depth (a). This change falls on a highly conserved residue (b) and lies within the cytoplasmic tail of
this transmembrane receptor (c). Three novel variants in WDR11 were found in our cohort—all of which affect a highly conserved residue (d)
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also possible that these genes/variants have an inter-
action with environmental cues in this population,
resulting in more common under-virilisation in CHH
than in other populations. Indeed, many of the described
patients come from low socio-economic communities,
and many of them are involved in agriculture. Both gen-
etic and environmental factors are thought to contribute
to isolated hypospadias (reviewed in [30]), and numerous
studies in different populations have shown agriculture
and pesticides to be a risk factor for reproductive develop-
ment and health, e.g. [31–34]. Finally, it is possible that
these variants detected in CHH genes are non-damaging
variants over-represented in the Indonesian population.
However, three patients had a PROKR2 variant previously
shown to be deleterious in functional studies, and we have
sequenced more than 100 individuals from Indonesia (in-
clude severe DSD patients, parents and siblings) who were
not enriched for these or other rare variants in CHH
genes (data not shown).
Mutations in PROK2 and PROKR2 are thought to
contribute to around 9% of patients with KS [23]. In our
cohort, a total of four patients had a variant in PROKR2
and one with PROK2. We also had three patients with
WDR11 variants, meaning this gene may also play a sig-
nificant role in Indonesian 46,XY DSD patients. Overall,
we have found eight variants in CHH genes that have
not been previously described in this disorder. Of these,
four are not present in online variant databases ExAC or
EVS. The PROKR2 variant p.W352G lies within the
cytoplasmic tail of this transmembrane receptor. Other
variants have been described in this region (such as
p.V331M—which we also found, and p.R357W) [21]. In
this case, the mutant residue (glycine) is smaller than
the wild-type residue and differs in hydrophobicity to
the wild-type residue (tryptophan). This may cause a loss
of external interactions in particular a loss of hydropho-
bic interactions with other molecules on the surface of
the protein. One patient had a variant in PROK2
(p.R23H) that has not been previously described. The af-
fected amino acid lies within the signal peptide region,
and the mutant residue (histidine) is smaller than the
wild-type residue and has a different charge (neutral
rather than positive). This may change the activity of the
signal peptide, and a patient with a variant affecting the
neighboring amino acid (p.A24P) has been described
previously in CHH [21].
The PROKR2 p.V331M variant that we and others
have found has been shown to have reduced functional
activity (albeit weaker than other variants) [21–23]; how-
ever, it is not predicted to be damaging by any of the
four prediction tools used. This is likely due to the fact
that several orthologous proteins in other species have a
methionine in this protein position. It has been sug-
gested that filtering variants based on currently available
pathogenicity tools may lead to under-reporting of such
compensated variants [35]. Therefore, while we have in-
cluded the in silico predictions of pathogenicity in our
pipeline, we have chosen to report all rare variants in
this manuscript regardless of these predictions.
Finally, two novel WDR11 variants were found in our
screen. WDR11 is predicted to exhibit two β propellers
made up of WD domains. Protein structure modelling
has predicted that WDR11 has 12 WD domains and that
nine of them (second through tenth) participate in the
genesis of two consecutive β propellers [36]. The
p.W803C variant in which a tryptophan is replaced by a
cysteine at position 803 falls within the 12th WD do-
main and is a highly conserved amino acid [36]. Cysteine
is a smaller residue than the wild-type residue, which
could interrupt with the WD function. The p.L427I
change is predicted to fall adjacent to WD domain 6,
where at least two other human variants have been
described [36].
Interestingly, we also found two patients with both
FGFR1 and CHD7 variants. Indeed, oligogenicity has
been described to be a feature of CHH (for a summary,
see [3]). Specifically, oligogenic inheritance has been pre-
viously reported for FGFR1, while no reports for CHD7
oligogenicity have yet been published. While CHD7 has
most frequently been associated with CHARGE syn-
drome, of which hypospadias can be a feature, a recent
paper has detailed patients in which CHD7 single-
nucleotide variants (SNVs) were not associated with
classical CHARGE syndromic features. Indeed, they
show that rare deleterious SNVs in this gene contribute
to the mutational burden of patients with both KS and
CHH in the absence of full CHARGE syndromic features
[37]. It may be that a combination of variant alleles in
FGFR1 and CHD7 can cause hypospadias and under-
virilisation. However, several of the FGFR1 and CHD7
variants had a total MAF of around 0.2%, with a preva-
lence of 0.3 or 0.4% in East Asia indicating that they
may be over-represented in the Indonesian population.
Further studies to address the pathogenicity of these var-
iants and the interaction between FGFR1 and CHD7 are
required and are beyond the scope of this study.
Hormonal analysis at the right age can be highly in-
formative in a clinical diagnosis of CHH. This includes
assays of the levels of the gonadotrophins FSH and LH,
as well as testosterone levels before and after hCG
stimulation. Diagnosis of KS and CHH in many of these
patients has been limited by access to detailed blood
hormone analysis (in particular as many are pre-
pubescent children meaning that measuring LH and
FSH is not informative). Most of our patients showed
low levels of testosterone (consistent with their age), but
these levels were stimulated by hCG. Nevertheless, the
genetic results of this study suggest that boys presenting
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with under-virilisation phenotypes in Indonesian clinics
should be tested for CHH or KS. The patients presented
here will be monitored as they develop, and we recom-
mend they have their gonadotrophin levels retested at a
later date when reduced levels can be detected.
A genetic diagnosis can inform family planning and
fertility investigations, as well as direct clinical manage-
ment. Treatments exist for many of the features of
CHH. In early life, this can include low-dose testoster-
one or gonadotrophins for micropenis and stimulation
of gonadal development. Later, during adolescence or
adulthood, testosterone therapy can also induce puberty
including psychosocial development [3]. CHH-associated
infertility can also be treated, for example, by adminis-
tering GnRH or gonadotrophins [3]. Thus, given the
therapeutic options, having a genetic diagnosis may
allow earlier or tailored intervention. Gene panel testing
is a viable option to deliver this genetic diagnosis.
Conclusion
We conclude that variants in CHH genes, in particular
PROKR2, PROK2, WDR11 and FGFR1 with CHD7, may
contribute to under-virilisation phenotypes including
hypospadias in Indonesian boys. We suggest that in this
population, 46,XY DSD patients should be monitored
for signs of CHH including hormonal and genetic
analysis.
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